Rapid antigen test

State of Delaware Selects Quidel for COVID-19 Testing Program at Schools

Retrieved on: 
Monday, July 19, 2021
Other Health, General Health, Pharmaceutical, Data management, Preschool, Medical devices, Technology, Other Education, Infectious diseases, Primary, Secondary, Education, Health, Medicine, Natural sciences, Branches of biology, Medical tests, Medical terminology, Quidel Corporation, Biotechnology, Chromatography, Molecular biology, Rapid diagnostic test, Rapid antigen test, COVID-19 testing

Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.
  • Students and faculty that opt-in to the COVID-19 screening program will be tested with Quidels rapid antigen tests.
  • DPH and Delawares Department of Education will launch the initiative at five pilot schools for summer school enrollees.
  • Quidel can expand the program to all of the States K-12 schools when classrooms fully reopen for the fall semester.

Trinity Biotech Provides A Business Development Update For Q2 2021

Retrieved on: 
Friday, July 16, 2021
Medicine, Branches of biology, Natural sciences, Immunologic tests, Medical tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test

DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.

Key Points: 
  • DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.
  • Trinity Biotech has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years.
  • In June 2021, the Company received an update from the WHO on the approval process.
  • Trinity Biotech is at an advanced stage in the development of a SARS-CoV-2 antigen test.

Ninonasal® Antigen Self-Tests Made in France

Retrieved on: 
Friday, July 16, 2021
Other Consumer, Medical devices, Infectious diseases, Hospitals, Other Health, Biotechnology, Managed care, Pharmaceutical, Consumer, Health, Medicine, Branches of biology, Medical tests, Natural sciences, Immunologic tests, Medical terminology, Chromatography, Molecular biology, Rapid antigen test

NG Biotech presents Ninonasal, the COVID-19 antigen self-test thats detecting Delta and Epsilon variants.

Key Points: 
  • NG Biotech presents Ninonasal, the COVID-19 antigen self-test thats detecting Delta and Epsilon variants.
  • View the full release here: https://www.businesswire.com/news/home/20210716005156/en/
    NG Biotech presents Ninonasal, the COVID-19 antigen self-test thats detecting Delta and Epsilon variants.
  • In France, Ninonasal is assembled into kits and distributed by Boiron Laboratories in order to strengthen its fully made in France character.
  • With Ninonasal, we did not just launch another rapid antigen test.

COVID-19: Doctor's certificates for antigen self-tests now offered online worldwide by DrAnsay.com

Retrieved on: 
Thursday, July 8, 2021
Medicine, Medical tests, Medical terminology, Branches of biology, Clinical medicine, Immunologic tests, Key management, Public key infrastructure, Rapid antigen test, Point-of-care testing, Public key certificate

HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.

Key Points: 
  • HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.
  • To obtain a test certificate online, the user first needs a standard antigen rapid self-test, which he performs himself at any time at any location.
  • Within three minutes he will receive the test certificate in 14 languages as a PDF file 24/7 after verification by an online doctor.
  • Only our efficient online service now quickly and easily allows millions of doctors' certificates of such self-applied tests worldwide," said lawyer and CEO Dr. jur.

COVID-19: Doctor's certificates for antigen self-tests now offered online worldwide by DrAnsay.com

Retrieved on: 
Thursday, July 8, 2021
Medicine, Medical tests, Medical terminology, Branches of biology, Clinical medicine, Immunologic tests, Key management, Public key infrastructure, Rapid antigen test, Point-of-care testing, Public key certificate

HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.

Key Points: 
  • HAMBURG, Germany, July 8, 2021 /PRNewswire/ -- DrAnsay.com, the market leader for online doctor attests, now offers online test certificates for self-applied rapid antigen tests worldwide to avoid the effort, infection risk and cost of point-of-care testing.
  • To obtain a test certificate online, the user first needs a standard antigen rapid self-test, which he performs himself at any time at any location.
  • Within three minutes he will receive the test certificate in 14 languages as a PDF file 24/7 after verification by an online doctor.
  • Only our efficient online service now quickly and easily allows millions of doctors' certificates of such self-applied tests worldwide," said lawyer and CEO Dr. jur.

Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests

Retrieved on: 
Wednesday, June 30, 2021
Medicine, Medical tests, Branches of biology, Life sciences, Medical terminology, Biotechnology, Areum, Chromatography, Molecular biology, Rapid antigen test, Rapid diagnostic test, COVID-19 rapid antigen test

The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.

Key Points: 
  • The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.
  • The distribution partnership between Vivera, Areum Bio, and Access Bio will help make rapid testing more readily available as quickly as possible.
  • "This co-branded collaboration marks a new strategic alliance for Vivera," said Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals.
  • "This is a great opportunity for Areum Bio to partner with Vivera, a reputable pharmaceutical company, for the nationwide distribution of the CareStart COVID-19 Rapid Antigen Tests," said Dr. Jong Kim, President of Areum Bio.

Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant

Retrieved on: 
Tuesday, June 29, 2021
Infectious diseases, Biotechnology, Health, Medical devices, Branches of biology, Medicine, Biology, Immunologic tests, Medical tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test, Affimer, Lateral flow test, Severe acute respiratory syndrome coronavirus 2

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially available in Europe.

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially available in Europe.
  • The AffiDX SARS-CoV-2 antigen lateral flow test has been evaluated with a small number of patient samples confirmed to be Delta variant positive and, for a Ct
  • The AffiDX SARS-CoV-2 antigen lateral flow test is CE marked for professional use in the UK and EU.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted to report that the AffiDX SARS-CoV-2 antigen lateral flow test detects the Delta variant with very high sensitivity for patients with a Ct value of less than 29.

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

 LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Distribution Agreement

Retrieved on: 
Monday, June 21, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical devices, Infectious diseases, Medicine, Branches of biology, Natural sciences, Medical tests, Immunologic tests, Medical terminology, Chromatography, Molecular biology, Rapid antigen test, Lateral flow test, Severe acute respiratory syndrome coronavirus 2

The non-exclusive distribution agreement for Avactas AffiDX SARS-CoV-2 antigen lateral flow test for professional use covers the UK and EEA.

Key Points: 
  • The non-exclusive distribution agreement for Avactas AffiDX SARS-CoV-2 antigen lateral flow test for professional use covers the UK and EEA.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted that we have put in place this distribution agreement for the AffiDX SARS-CoV-2 antigen lateral flow test for professional use with Calibre.
  • Avacta will continue to focus on developing direct sales opportunities to major corporates and other large scale end users.
  • Lateral flow tests have a crucial role to play in helping societies and the global economy return to normal and Avactas AffiDX antigen test, developed in the UK and based on UK technology is well placed to play a significant role in this process.